-
Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia Leukemia (IF 13.4) Pub Date : 2025-06-24 Delphine Lebon, Audrey Da Rocha, Bruno Cassinat, Maël Heiblig, Sarah Bertoli, Caroline Bonmati, Anne Zilliox, Marie Laloi, Céline Berthon, Nicolas Duployez, Christophe Willekens, Maria Pilar Gallego Hernanz, Marlène Ochmann, Thomas Cluzeau, Fatiha Chermat, Alexis Caulier, Christian Récher, Mathilde Hunault-Berger, Emmanuel Raffoux, Pierre Fenaux, Jean Pierre Marolleau, Lionel Adès
-
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes Leukemia (IF 13.4) Pub Date : 2025-06-24 Clifford M. Csizmar, Anuya Natu, Mark Gurney, Saubia Fathima, Ali Khalid A. Alsugair, Rashmi Kanagal-Shamanna, Sanam Loghavi, Alexandre Bazinet, Kelly Chien, Danielle Hammond, Courtney DiNardo, Tapan Kadia, Farhad Ravandi-Kashani, Naveen Pemmaraju, Koji Sasaki, Terra L. Lasho, Christy M. Finke, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Naseema Gangat, Mehrdad Hefazi Torghabeh, Aasiya Matin, Abhishek
-
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice Leukemia (IF 13.4) Pub Date : 2025-06-24 Piers Blombery, Thomas Chatzikonstantinou, Marina Gerousi, Richard Rosenquist, Gianluca Gaidano, Sarka Pospisilova, Andrew W. Roberts, Richard W. Birkinshaw, Davide Rossi, Lydia Scarfo, John F. Seymour, Stephan Stilgenbauer, Adrian Wiestner, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Kostas Stamatopoulos
-
Critical roles of IKAROS and HDAC1 in regulation of heterochromatin and tumor suppression in T-cell acute lymphoblastic leukemia Leukemia (IF 13.4) Pub Date : 2025-06-24 Yali Ding, Bing He, Daniel Bogush, Joseph Schramm, Chingakham Singh, Katarina Dovat, Julia Randazzo, Diwakar Tukaramrao, Jeremy Hengst, Charyguly Annageldiyev, Avinash Kudva, Dhimant Desai, Arati Sharma, Vladimir S. Spiegelman, Suming Huang, Chi T. Viet, Glenn Dorsam, Giselle Saulnier Scholler, James Broach, Feng Yue, Sinisa Dovat
-
Deciphering cholangiocarcinoma heterogeneity and specific progenitor cell niche of extrahepatic cholangiocarcinoma at single-cell resolution J. Hematol. Oncol. (IF 40.4) Pub Date : 2025-06-23 Chunliang Liu, Xiang Wang, Erdong Liu, Yali Zong, Wenlong Yu, Youhai Jiang, Jianan Chen, Mingye Gu, Zhengyuan Meng, Jingfeng Li, Yang Liu, Yongjie Zhang, Jing Tang, Hongyang Wang, Jing Fu
Cholangiocarcinoma (CCA) is a highly heterogeneous malignancy, primarily comprising intrahepatic (iCCA) and extrahepatic (eCCA) subtypes. Reconciling the variability between iCCAs and eCCAs in clinical trials remains a challenge, largely due to the inadequate understanding of their shared and subtype-specific cellular heterogeneity. We aim to address this issue using single-cell and spatially resolved
-
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia Leukemia (IF 13.4) Pub Date : 2025-06-23 Kiyomi Mashima, Yanan Kuang, Stacey M. Fernandes, Shidong Xu, Benjamin Hanna, Samantha Shupe, Mariia Mikhaleva, Roberta Azevedo Santos, Paulina Predko, Rayan Fardoun, Ava Bidgoli, Stephen P. Martindale, Aishath Naeem, Matthew S. Davids, Cloud Paweletz, Jennifer R. Brown
-
Frailty, Genetic Risk, and Long‐Term Risk of Venous Thromboembolism: Insight From a UK Biobank Study Am. J. Hematol. (IF 9.9) Pub Date : 2025-06-23 Jiatang Xu, Qiushi Ren, Yangfan Su, Liling Lin, Runnan Shen, Kai Huang
Frailty is more prevalent among venous thromboembolism (VTE) patients. However, the relationship between long‐term VTE risk and frailty remained unexplored. This study included 315 523 participants recruited from UK Biobank between 2006 and 2010. Frailty status of participants at recruitment was evaluated by physical frailty and frailty index. The association between frailty and long‐term risk of VTE
-
Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study Blood Cancer J. (IF 11.6) Pub Date : 2025-06-21 Frederique St-Pierre, Subodh Bhatta, Peter G. Doukas, Madeline Jenkin, Kaitlin Annunzio, Alexandra E. Rojek, Alyssa Gibson, Yun Kyoung Tiger, Brittany McCall, Khaled Alhamad, Alec Hansen, Juan P. Alderuccio, Olutobi Adewale, Keem Patel, Asaad Trabolsi, Izidore S. Lossos, Lindsey Fitzgerald, Thomas A. Ollila, Matthew J. Matasar, Justin Kline, Reem Karmali, Narendranath Epperla
-
Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors. Blood (IF 23.1) Pub Date : 2025-06-20 Jaclyn Andricovich,Coen Johannes Lap,Alexandros Tzatsos
Mutations in TP53 are mutually exclusive with other known drivers of myeloid transformation and define a distinct molecular subtype within de novo Acute Myeloid Leukemia (AML) that is associated with a complex karyotype, resistance to chemotherapy, and poor prognosis. Although TP53 defects are rare in de novo AML, biallelic mutations are a defining molecular feature of erythroleukemia. The genetic
-
LRRC8 complexes are ATP release channels regulating platelet activation and arterial thrombosis. Blood (IF 23.1) Pub Date : 2025-06-20 John David Tranter,Ryan Takayuki Mikami,Ashutosh Kumar,Gavriel Brown,Tarek Mohamed Abd El-Aziz,Yonghui Zhao,Prakash Arullampalam,Katrina J Ashworth,Vishwanath Jha,Nihil Abraham,Chloe Meyer,Abigail Ajanel Gomez,Litao Xie,Yongmei Feng,Juan Hong,Haixia Zhang,Tripti Kumari,Adam Balutowski,Alice Liu,David Bark,Vinayak K Nair,Nina M Lasky,Nathan O Stitziel,Daniel J Lerner,Robert A Campbell,Jorge Di Paola
Platelet shape and volume changes are early mechanical events contributing to platelet activation and thrombosis. Here, we identify single-nucleotide polymorphisms in Leucine-Rich Repeat Containing 8 (LRRC8) protein subunits that form the Volume-Regulated Anion Channel (VRAC) which are independently associated with altered mean platelet volume. LRRC8A is required for functional VRAC in megakaryocytes
-
Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell Lymphoma. Blood (IF 23.1) Pub Date : 2025-06-20 Shinya Rai,Gerben Duns,Fabian Frontzek,Jasper Chun Hei Wong,Yifan Yin,Michael Y Li,Makoto Kishida,Manabu Fujisawa,Shannon Healy,Elena Viganò,Aixiang Jiang,Bruce Woolcock,Adèle Telenius,Susana Ben-Neriah,Barbara Meissner,Merrill Boyle,Hisae Nakamura,Luke O Brien,Claudia Cassidy,Andrew Lytle,Pedro Farinha,Graham W Slack,Laura K Hilton,Ryan D Morin,Leandro Venturutti,Tomohiro Aoki,Nicole Wretham,Jonathan
Disease-defining signatures in lymphomas, driven by intricate molecular mechanisms, have advanced molecular taxonomies, refined classification, and may guide clinical management; however, the role of these signatures in driving disease hallmarks including subtype-specific organotropism remains largely unexplored. Primary mediastinal large B-cell lymphoma (PMBCL) is an exemplary lymphoma characterized
-
Bone marrow neutrophil progenitors suppress osteoclast formation in murine cortical and trabecular bone. Blood (IF 23.1) Pub Date : 2025-06-20 Tsuyoshi Isojima,Blessing Crimeen-Irwin,Narelle E McGregor,Ryan C Chai,Ingrid J Poulton,Emma C Walker,Mriga Dutt,Benjamin L Parker,Natalie A Sims
In inflammation, circulating neutrophils indirectly damage the skeleton by inducing formation of bone-resorbing osteoclasts. However, neutrophil progenitors in marrow have no known physiological function. A bone-protective role for the neutrophil lineage was recently suggested when a profound defect in bone structure was observed in mice with neutropenia due to Granulocyte Colony Stimulating Factor
-
Impact of Duffy Status on Neutrophil Counts and Clinical Outcomes in Pediatric Patients With Sickle Cell Disease Am. J. Hematol. (IF 9.9) Pub Date : 2025-06-20 Yan Zheng, Jeffrey Gossett, Pei‐Lin Chen, Guolian Kang, Clifford M. Takemoto
The Duffy-null phenotype is prevalent in individuals of African and Middle Eastern ancestry. It is associated with lower absolute neutrophil counts (ANCs), which are termed Duffy-null associated neutrophil counts (DANCs) [1]. The Duffy blood group consists of two main antigens, Fya and Fyb, and is encoded by the atypical chemokine receptor 1 (ACKR1) gene. Homozygosity for a SNP (rs2814778; T>C; CC)
-
International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis Am. J. Hematol. (IF 9.9) Pub Date : 2025-06-20 Midori Filiz Nishimura, Tomoka Haratake, Yoshito Nishimura, Asami Nishikori, Remi Sumiyoshi, Hideki Ujiie, Yuri Kawahara, Tomohiro Koga, Masao Ueki, Dorottya Laczko, Eric Oksenhendler, David C. Fajgenbaum, Frits van Rhee, Atsushi Kawakami, Yasuharu Sato
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder classified into three recognized clinical subtypes—idiopathic plasmacytic lymphadenopathy (IPL), TAFRO, and NOS. Although clinical criteria are available for subtyping, diagnostically challenging cases with overlapping histopathological features highlight the need for an improved classification system integrating
-
Thromboembolic Events Are Increased After Splenectomy in Postmenopausal Women Am. J. Hematol. (IF 9.9) Pub Date : 2025-06-20 Qi Feng, Yi Mu, Christopher Kabrhel, Bernard Rosner, Rulla M. Tamimi, James B. Bussel
In the United States, 22 000 splenectomies are performed annually [1] for various conditions. Splenectomy has been linked to overwhelming sepsis and more recently to thromboembolic events (TEE) [2-5]. Danish national registry studies documented the increased occurrence of TEE postsplenectomy; however, earlier studies were restricted to males and later ones, including two Danish studies, did not discriminate
-
A molecular signature predicts hematologic evolution in polycythemia vera patients Leukemia (IF 12.8) Pub Date : 2025-06-18 Olivier Mansier, Eric Lippert, Lina Benajiba, Dana Ranta, François Girodon, Jean-Christophe Ianotto, Aurélie Chauveau, Lydia Roy, Françoise Boyer, Clémence Médiavilla, Suzanne Tavitian, Marion Divoux, Mélinda Fanet, Ivan Sloma, Véronique De Mas, Guillaume Denis, Christopher Nunes Gomes, Claire Calmettes, Fiorenza Barraco, Sarah Huet, Fabienne Vacheret, Mélanie Mercier, Anne Parry, Laurence Legros,
-
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia Leukemia (IF 12.8) Pub Date : 2025-06-18 Filippo Vit, Tamara Bittolo, Antonella Zucchetto, Robel Papotti, Erika Tissino, Federico Pozzo, Annalisa Gaglio, Andrea Stacchetti, Eva Zaina, Ilaria Cattarossi, Paola Varaschin, Paola Nanni, Michele Berton, Alessandra Braida, Francesca Maria Rossi, Massimo Degan, Jerry Polesel, Roberta Laureana, Annalisa Chiarenza, Jacopo Olivieri, Annalisa Biagi, Giovanni D’Arena, Marco Rossi, Luca Laurenti, Agostino
-
Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy J. Hematol. Oncol. (IF 40.4) Pub Date : 2025-06-19 Qin Hu, Yifei Zhu, Jie Mei, Ying Liu, Guoren Zhou
The extracellular matrix (ECM), closely linked to the dynamic changes in the tumor microenvironment (TME), plays a critical role in modulating tumor immunity. The dual role of the ECM in tumor progression, encompassing both promotion and inhibition, is attributed to its components influencing immune cell activation, migration, and infiltration. This mechanism is intricately connected with the efficacy
-
-
-
-
-
Access to AlloTx for AML: the value of the social phenotype Blood (IF 21.0) Pub Date : 2025-06-19 Gary Schiller
-
Disrupting HIT immune complexes as a new treatment for HIT Blood (IF 21.0) Pub Date : 2025-06-19 Beng H. Chong
-
-
-
Severe oxidant hemolysis in a child with G6PD deficiency and Hb C trait Blood (IF 21.0) Pub Date : 2025-06-19 Connor Cocke, Weijie Li
-
A natural head start to MRD negativity in multiple myeloma Blood (IF 21.0) Pub Date : 2025-06-19 Erin W. Meermeier
-
-
Precision pre-HSCT conditioning by targeting cMPL Blood (IF 21.0) Pub Date : 2025-06-19 Markus G. Manz
-
MRD and NK‐Cell Chimerism Predict Transplant Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation Recipients Am. J. Hematol. (IF 9.9) Pub Date : 2025-06-19 Xing Chen, Huihong Huang, Weihao Chen, Yeqian Zhao, Chuanhe Jiang, Luxiang Wang, Zengkai Pan, Jiayu Huang, Zilu Zhang, Haiyang Lu, Yan Sheng, Xiangqin Weng, Yanmin Zhao, Yang Cao, Xiaoxia Hu
-
Luspatercept in Transfusion‐Dependent β‐Thalassemia: The Benefit Is Real, and So Are the Risks Am. J. Hematol. (IF 9.9) Pub Date : 2025-06-19 Khaled M. Musallam
Luspatercept, an erythroid maturation agent promoting late-stage erythropoiesis, has been approved for the treatment of anemia in adult patients with transfusion-dependent β-thalassemia (TDT) since 2019. The marketing authorization was based on data from the phase 3 BELIEVE trial which showed that 21.4% of 224 patients had at least a 33% reduction in their transfusion requirement compared to 4.5% of
-
Efficacy and Safety of Hetrombopag Versus Thrombopoietin in Promoting Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial Am. J. Hematol. (IF 9.9) Pub Date : 2025-06-19 Yimei Feng, Linhui Wang, Mingqiang Ren, Dan Wang, Tao Lang, Jianchuan Deng, Shifeng Lou, Hai Yi, Liangliang Ma, Hongyun Xing, Pengcheng He, Xiaoning Wang, Sanbin Wang, Jishi Wang, Han Yao, Ting Chen, Jia Liu, Lu Zhao, Yuqing Liu, Xiaoqi Wang, Li Li, Shuhan Tang, Lidan Zhu, Jia Liu, Shichun Gao, Huanfeng Liu, Lu Wang, Peiyan Kong, Lei Gao, Xi Zhang
Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is pivotal for hematological malignancies but faces challenges in delayed platelet engraftment, poor graft function (PGF), and bleeding risks. Hetrombopag, a thrombopoietin receptor agonist, was evaluated to enhance platelet recovery posttransplant. Patients undergoing allo‐HSCT were randomized on Day 3 Post‐Infusion into low‐dose (2.5
-
Characterization, outcome and identification of prognostic factors for patients with systemic immunoglobulin light-chain amyloidosis requiring dialysis prior to initial anti-clonal therapy. Haematologica (IF 8.2) Pub Date : 2025-06-19 Lilli S Sester,Paolo Milani,Fenia Theodorakakou,Tobias Dittrich,Jörg Beimler,Fabian Aus dem Siepen,Martin Zeier,Marc-Steffen Raab,Carsten Müller-Tidow,Efstathios Kastritis,Giovanni Palladini,Ute Hegenbart,Stefan O Schönland
AL amyloidosis is a serious disease characterized by the deposition of immunoglobulin light chains in multiple organs. Renal involvement occurs in up to 70% of patients, but only a minority require dialysis before initiating anti-clonal treatment. Understanding the occurrence of end-stage organ damage is crucial to pave the way for reversing deposition. Currently, there is no detailed analysis available
-
Olverembatinib in chronic myeloid leukemia: is less actually better? Haematologica (IF 8.2) Pub Date : 2025-06-19 Maria Agustina Perusini,Dennis Dong Hwan Kim
Not available.
-
Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single institution retrospective study of 66 patients. Haematologica (IF 8.2) Pub Date : 2025-06-19 Suheil Albert Atallah-Yunes,Matthew J Rees,Thomas M Habermann,Yucai Wang,Javier Munoz,Madiha Iqbal,Jose C Villasboas,Ellen D McPhail,Thomas E Witzig,Stephen M Ansell,Grzegorz S Nowakowski
Not available.
-
Optical genome mapping reveals complex cytogenetic abnormalities in multiple myeloma. Haematologica (IF 8.2) Pub Date : 2025-06-19 Jorge A Palacios,Mónica Bernal,Jose R Vílchez,Pilar Garrido,Pilar Jiménez,Juan F Gutiérrez-Bautista,María C Barrera-Aguilera,Lucía Ballesta,Teresa Rodríguez,María J Olivares-Durán,Francisco Ruiz-Cabello
Not available.
-
Randomized trial of anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide to prevent graft-versus-host disease in haploidentical transplantation. Haematologica (IF 8.2) Pub Date : 2025-06-19 Zheng-Li Xu,Ting-Ting Han,Xiao-Lu Zhu,Jing Liu,Meng Lv,Yu-Qian Sun,Xiao-Dong Mo,Yi-Fei Cheng,Lan-Ping Xu,Xiao-Hui Zhang,Xiao-Jun Huang,Yu Wang
The combination of anti-thymocyte globulin (ATG) and posttransplant cyclophosphamide (PTCy) appears to be a potentially effective graft-versus-host disease (GVHD) prevention strategy for haploidentical transplantation. However, the majority of the evidence originated from retrospective studies without uniform protocols. Our previous findings indicated that 10 mg/kg ATG plus low-dose PTCy could decrease
-
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies. Haematologica (IF 8.2) Pub Date : 2025-06-19 Binu Kandathilparambil Sasi,Chiara Tarantelli,Stephen Martindale,Elisa Civanelli,Eleonora Cannas,Giulio Sartori,Alberto J Arribas,Stacey M Fernandes,Samantha J Shupe,John-Hanson Machado,Svitlana Tyekucheva,Yue Ren,Michael Lahn,Lars Van der Veen,Giusy Di Conza,Francesco Bertoni,Jennifer R Brown
The phosphoinositide 3-kinase (PI3K) pathway remains a potent drug target in hematological malignancies despite the challenges that have affected clinical drug development, particularly unpredictable toxicity, and inherent/acquired drug resistance. Herein, we tested the activity of a novel PI3Kδ selective, non-ATP competitive inhibitor, roginolisib (IOA-244), in hematological malignancies including
-
Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma. Haematologica (IF 8.2) Pub Date : 2025-06-19 Andrew J Portuguese,Emily C Liang,Jennifer J Huang,Yein Jeon,Danai Dima,Rahul Banerjee,Mary Kwok,Kara I Cicero,Alexandre V Hirayama,Ryan Basom,Christy Khouderchah,Mazyar Shadman,Lawrence Fong,Andrew J Cowan,Jordan Gauthier
Extramedullary disease (EMD) in multiple myeloma (MM) is associated with poor outcomes following B-cell maturation antigen (BCMA)-targeted CAR-T therapy, yet its impact on treatment-related toxicity remains unclear. This study evaluates the impact of active EMD on toxicity, efficacy, and survival in patients with MM treated with idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel)
-
Radiopsy: a prospective observational study on quantitative multiparametric whole-body magnetic resonance imaging to discriminate between smoldering and multiple myeloma. Haematologica (IF 8.2) Pub Date : 2025-06-19 Giacomo Feliciani,Emiliano Loi,Elena Amadori,Eleonora Antognoni,Andrea Prochowski Iamurri,Danila Diano,Daniele Bruno,Arrigo Cattabriga,Paola Caroli,Matteo Marchesini,Davide Bezzi,Delia Cangini,Federica Matteucci,Domenico Barone,Davide Nappi,Gerardo Musuraca,Michela Ceccolini,Sonia Ronconi,Irene Azzali,Giovanni Martinelli,Lorenzo Stefano Maffioli,Nicola Normanno,Anna Sarnelli,Alice Rossi,Claudio Cerchione
Not available.
-
Elevated 5-HTR7 deteriorates dysregulated megakaryocytopoiesis in immune thrombocytopenic purpura via up-regulating the PKA/Orai1/ERK1/2 pathway. Haematologica (IF 8.2) Pub Date : 2025-06-19 Meng Zhou,Haohao Han,Jiaqian Qi,Ziyan Zhang,Xiaofei Song,Xueqian Li,Tiantian Chu,Depei Wu,Yue Han
Dysregulated megakaryocytopoiesis contributes to reduced platelet counts in immune thrombocytopenic purpura (ITP), yet the mechanism remains elusive. Although 5-hydroxytryptamine receptor 7 (5-HTR7) has been implicated in megakaryocyte (MK) biology, its pathogenic involvement in ITP is undefined. This study investigated the impact of 5-HTR7 on MK maturation in ITP using flow cytometry, immunofluorescence
-
TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Haematologica (IF 8.2) Pub Date : 2025-06-19 Lin Li,Yishan Ye,Jacques-Emmanuel Galimard,Myriam Labopin,Depei Wu,Jia Chen,Nicolaus Kröger,Jakob Passweg,Urpu Salmenniemi,Maija Itäla-Remes,Xavier Poiré,Matthias Eder,Johan Maertens,David Burns,Henrik Sengeloev,Gitte Olesen,Didier Blaise,Jürgen Finke,Alain Gadisseur,Ali Bazarbachi,Eolia Brissot,Arnon Nagler,Yi Luo,Jimin Shi,Mohamad Mohty,He Huang,Fabio Ciceri,Norbert Claude Gorin
Not available.
-
Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study. Haematologica (IF 8.2) Pub Date : 2025-06-19 Lucas Maahs,Ana Maria Avila,Matthew Koshy,Karen Sweiss,Kang-Hyun Ahn,Zhengjia Chen,Chukwuemeka Uzoka,Carlos Galvez,Matias Sanchez,Paul Rubinstein,John Quigley,Elisa Zucchetti,Nadim Mahmud,Bulent Aydogan,Pritesh Patel,Damiano Rondelli
The intensity of the conditioning regimen in hematopoietic stem cell transplantation (HSCT) correlates with the risk of relapse, however its potential benefit may be outweighed by the associated risk of toxicity. The addition of total marrow irradiation (TMI) to myeloablative conditioning provides an opportunity to increase intensity with minimal additional toxicity. In this phase 2 clinical trial
-
Comparison of Frontline Therapies in Older Adults Age ≥ 80 Years With Chronic Lymphocytic Leukemia (CLL): A Mayo Clinic and Danish Nation-Wide Study Am. J. Hematol. (IF 10.1) Pub Date : 2025-06-18 Mazie Tsang, Paul J. Hampel, Kari G. Rabe, Christian Brieghel, Wei Ding, Jose F. Leis, Talal Hilal, Saad S. Kenderian, Yucai Wang, Eli Muchtar, Amber B. Koehler, Daniel L. Van Dyke, Curtis A. Hanson, Min Shi, Susan L. Slager, Neil E. Kay, Henrik Hjalgrim, Carsten U. Niemann, Sameer A. Parikh, Emelie C. Rotbain
People with chronic lymphocytic leukemia (CLL) have a median age at diagnosis of around 70 years [1]. With an average time to first treatment of 4–5 years from diagnosis, it is estimated that a third of all people with CLL will be ≥ 80 years old when they become symptomatic and receive frontline therapy [1]. People ≥ 80 years old often have comorbidities and unfavorable disease characteristics (like
-
Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma Am. J. Hematol. (IF 10.1) Pub Date : 2025-06-13 Alyssa Bouska, Weiwei Zhang, Sunandini Sharma, Harald Holte, Rauf A. Shah, Waseem G. Lone, Mahfuza Afroz Soma, Ruimeng Yang, Xuxiang Liu, Syed Mehmood, Ravneet Singh Chawla, Luca Vincenzo Cappelli, Danilo Fiore, Qiang Gong, Tayla B. Heavican-Foral, Jeffrey J. Cannatella, Catalina Amador, Aiza Arif, Lynette M. Smith, Soon Thye Lim, Choon Kiat Ong, Andrew L. Feldman, Ming-Qing Du, Anamarija M. Perry
Nodal follicular helper T-cell (TFH) lymphoma of the angioimmunoblastic (AITL) subtype has a dismal prognosis. Using whole-exome sequencing (n = 124), transcriptomic (n = 78), and methylation (n = 40) analysis, we identified recurrent mutations in known epigenetic drivers (TET2, DNMT3A, IDH2R172) and novel ones (TET3, KMT2D). TET2, IDH2R172, DNMT3A co-mutated AITLs had poor prognosis (p < 0.0001).
-
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group Blood Cancer J. (IF 12.9) Pub Date : 2025-06-18 Xinyan Lu, Erica F. Andersen, Rahul Banerjee, Celeste C. Eno, Patrick R. Gonzales, Shaji Kumar, Angela M. Lager, Patricia M. Miron, Trevor Pugh, Fabiola Quintero-Rivera, Virginia C. Thurston, Daynna J. Wolff, Jian Zhao, Rafael Fonseca, Linda B. Baughn
-
TNFα signaling restores steady-state hematopoiesis in anemia of inflammation TNFαKO mouse model Blood (IF 21.0) Pub Date : 2025-06-18 Amaliris Guerra, Vania Lo Presti, Ding-Wen Chen, Ana Catarina Martins, Ariel Rivera, Nolan Hamilton, Pankja Sharma, Yelena Z. Ginzburg, Carlo Castruccio Castracani, Carla Casu, Ritama Gupta, Raffaella Gozzelino, Edward M. Behrens, Laura F. Bennett, Robert F. Paulson, Peter Kurre, Stefano Rivella
Anemia of inflammation (AI) is the second most common form of anemia and is prevalent in patients with chronic inflammatory states, such as infection, autoimmunity, and cancer. Interleukin 6 (IL6) is well-known to induce the iron-sequestering hormone hepcidin, which results in iron-restricted anemia. The contributions of other pro-inflammatory cytokines such as tumor necrosis factor-α (TNFα) and interferon-γ
-
Hereditary Elliptocytosis Resulting From Heterozygosity for β Spectrin Tandil Am. J. Hematol. (IF 9.9) Pub Date : 2025-06-18 María‐Angustias Molina‐Arrebola, Barbara J. Bain
A 57-year-old Spanish woman was referred for investigation of chronic anemia. Her mother and grandmother also had a history of anemia. There was no jaundice and no abdominal pain or tenderness, but abdominal ultrasonography showed homogeneous splenomegaly, the spleen measuring 14.2 cm. She had required a transfusion on one occasion when the hemoglobin concentration (Hb) fell to 71 g/L. Her blood count
-
Correction: Ube2v1-mediated ubiquitination and degradation of Sirt1 promotes metastasis of colorectal cancer by epigenetically suppressing autophagy J. Hematol. Oncol. (IF 29.5) Pub Date : 2025-06-17 Tong Shen, Ling-Dong Cai, Yu-Hong Liu, Shi Li, Wen-Juan Gan, Xiu-Ming Li, Jing-Ru Wang, Peng-Da Guo, Qun Zhou, Xing-Xing Lu, Li-Na Sun, Jian-Ming Li
Correction to: Journal of Hematology & Oncology (2018) 11:95. https://doi.org/10.1186/s13045-018-0638-9 During figure preparation, an incorrect representative image was included in Figs. 1e, S5B, and S6C. These errors occurred during figure assembly and do not affect the results or conclusions of the study. The corrected figures have been provided. The authors apologize for the errors and any confusion
-
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting J. Hematol. Oncol. (IF 29.5) Pub Date : 2025-06-17 Gejia Cao, Haixiao Zhang, Shu Sun, Hong-Hu Zhu
Menin inhibitors, which target the KMT2A-menin protein-protein interaction to inhibit blasts proliferation and induce differentiation, have demonstrated potential effects on acute leukemia subtypes characterized by overexpression of HOXA gene cluster and MEIS1 (including KMT2A rearrangements, NPM1 mutations, NUP98 rearrangements and other genetic alterations). Following the promising outcomes of the
-
A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM) Blood Cancer J. (IF 12.9) Pub Date : 2025-06-17 Chandramouli Nagarajan, Wei-Ying Jen, Melissa Ooi, Sanjay De Mel, Cinnie Soekojo, Sung Soo Yoon, Melinda Tan, Yunxin Chen, Xinhua Li, Yogesh Pokharkar, Shi Ning Tham, Nur Shahidah Binte Hashim, Neha Awasthi, Sarah M. Burkill, Brian Durie, Wee Joo Chng
-
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management Am. J. Hematol. (IF 9.9) Pub Date : 2025-06-17 Shai Shimony, Marlise R. Luskin, Naseema Gangat, Nicole R. LeBoeuf, Angela M. Feraco, Andrew A. Lane
-
Issue Information Am. J. Hematol. (IF 9.9) Pub Date : 2025-06-17
Click on the article title to read more.
-
RhoA GAP Myo9b regulates β2-integrin activity and neutrophil recruitment during murine acute kidney injury Blood (IF 21.0) Pub Date : 2025-06-16 Anika Cappenberg, Marina Oguama, Mathis Richter, Andreas Margraf, Wida Amini, Pia Lindental, Sina Mersmann, Bernadette Bardel, Helena Block, Thomas Vogl, Oliver Soehnlein, Klaus Ley, Jan Rossaint, Alexander Zarbock
An acute inflammatory response to infection or sterile injury involves an adequate activation and recruitment of leukocytes. Activation of β2-integrins is required for neutrophil recruitment and is also mandatory for various neutrophil cell-intrinsic functions. GTPases are key regulators of the actin cytoskeleton and are required for β2‐integrin activation. MyosinIXb (Myo9b), a Rho GTPase-activating
-
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma Blood (IF 21.0) Pub Date : 2025-06-16 Benjamin Diamond, Linda Baughn, Mansour Poorebrahim, Alexandra M. Poos, Holly Lee, Marcella Kaddoura, J. Erin Wiedmeier-Nutor, Michael Durante, Gregory Otteson, Dragan Jevremovic, Hongwei Tang, Stefan Fröhling, Marc A. Baertsch, Marios Papadimitriou, Bachisio Ziccheddu, Tomas Jelinek, Cendrine Lemoine, Alexey Rak, Damian J. Green, Ola Landgren, Paola Neri, Leif Bergsagel, Esteban Braggio, Shaji Kumar
Monoclonal antibodies targeting CD38 are a therapeutic mainstay in multiple myeloma (MM). Although they have contributed to improved outcomes, most patients still experience disease relapse, and little is known about tumor-intrinsic mechanisms of resistance to these drugs. Antigen escape has been implicated as a mechanism of tumor-cell evasion in immunotherapy. Yet, it is unknown whether MM cells can
-
An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4-mediated ferritinophagy as a dependence in Tet2-deficient hematopoiesis Blood (IF 21.0) Pub Date : 2025-06-16 Justin Loke, Peter G. Kim, Thuy T.P. Nguyen, Meaghan Boileau, Marie McConkey, Aidan Miller, Wesley Shin, Christopher B. Hergott, Maria Ericsson, Anja Nordstrom, Paula Montero Llopis, Scott Armstrong, Joseph D. Mancias, Benjamin L. Ebert
TET2 is among the most commonly mutated genes in both clonal hematopoiesis and myeloid malignancies; thus, the ability to identify selective dependencies in TET2-deficient cells has broad translational significance. Here, we identify regulators of Tet2 knockout (KO) hematopoietic stem and progenitor cell (HSPC) expansion using an in vivo CRISPR-Cas9 KO screen, in which nucleotide barcoding enabled
-
The T follicular helper/T follicular helper regulatory pathway in FVIII immune responses in mice Blood (IF 21.0) Pub Date : 2025-06-16 Weiqing Jing, Jocelyn A. Schroeder, Saurabh Kumar, Juan Chen, Yuanhua Cai, Lynn M. Malec, Alexander L. Dent, Weiguo Cui, Qizhen Shi
Developing anti–factor VIII (FVIII) inhibitory antibodies (inhibitors) are a significant complication of FVIII protein replacement therapy in hemophilia A. Our previous study demonstrated that follicular helper T (TFH) cells play a critical role in FVIII inhibitor development. Follicular regulatory T (TFR) cells are a subset of Foxp3+ T cells recently identified in the germinal center that can modulate
-
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial Lancet Haematol. (IF 15.4) Pub Date : 2025-06-15 Prof Elias Jabbour MD, Federico Lussana MD, Pilar Martínez-Sánchez MD, Anna Torrent MD, José J Rifón MD, Vaibhav Agrawal MD, Mar Tormo MD, Ryan D Cassaday MD, Thomas Cluzeau MD, Françoise Huguet MD, Cristina Papayannidis MD, Jesús M Hernández-Rivas MD, Anita Rijneveld MD, Shaun Fleming MD, Vladan Vucinic MD, Boris Böll MD, Takayuki Ikezoe MD, Maher Abdul-Hay MD, Mary L Savoie MD, Andre C Schuh MD,
Two doses of subcutaneous blinatumomab in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia were identified as preliminary recommended phase 2 doses, based on the dose-escalation phase of this multicentre single-arm, phase 1/2 trial. Here, we aim to further study the safety, activity, and pharmacokinetics of these doses in all participants who have received them, including those
-
Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma Blood Cancer J. (IF 12.9) Pub Date : 2025-06-13 Ji Yun Lee, Kui-Jin Kim, Woochan Park, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Tae Min Kim, Jin Ho Paik